Cedar Mountain Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Cedar Mountain Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$218	Buy	+3	New	+$231	﹤0.01%	1102

Other funds holding ANIP

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Ranger Investment Management Dallas, Texas $1.07B AUM 31.98% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Mizuho Markets Americas New York $6.82B AUM 29.92% 1-Year Est. Return

Cedar Mountain Advisors's ANIP Position: Q3 2026 in Review

Cedar Mountain Advisors opened a new position in ANI Pharmaceuticals (ANIP) in Q3 2026: 3 shares worth $218. The stake represents ﹤0.01% of the portfolio and ranks #1102 among its holdings.

147 funds tracked by Wall St. Rank hold ANIP as of Q3 2026.

Cedar Mountain Advisors held 3 shares of ANI Pharmaceuticals worth $218 as of Q3 2026.
ANI Pharmaceuticals was a new Cedar Mountain Advisors position in Q3 2026.
ANI Pharmaceuticals made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q3 2026, its #1102 holding.
147 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2026.

Based on Cedar Mountain Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.